Key Points - Rosen Law Firm reminds investors of the October 27, 2026 lead plaintiff deadline for a securities class action against Hyliion Holdings Corp. - Kaplan Fox urges investors who suffered losses to contact them and join the lawsuit against Hyliion Holdings Corp. - Faruqi & Faruqi, LLP is investigating potential claims against Hyliion...
Vaxart, Inc. (VXRT) is currently $0.4400 — here's the support-and-resistance map drawn from swing pivots, volume...
Vicarious Surgical Inc. (RBOT) closed at $0.0881 Thursday, up 10.1% on the session.Vicarious Surgical rose 10.13%...
Rather than pick a side, this is the evidence on each. Kopin Corp. (KOPN) currently shows...
Inspired Entertainment, Inc. (INSE) gives both camps something to hold. These are the 5 bullish and...
David Nierengarten from Wedbush issued a price target of $14.00 for STTK on 2026-10-02 11:42:04.The adjusted price target was set to $14.00.At the time of the announcement, STTK was trading...
Joseph Stringer from Needham issued a price target of $19.00 for STTK on 2026-10-02 11:05:00.The adjusted price target was set to $19.00.At the time of the announcement, STTK was trading...
Manuel Navas from Piper Sandler issued a price target of $12.00 for MFIN on 2026-10-02 10:59:49.The adjusted price target was set to $12.00.At the time of the announcement, MFIN was...
from Guggenheim issued a price target of $5.00 for FHTX on 2026-10-02 10:49:43.The adjusted price target was set to $5.00.At the time of the announcement, FHTX was trading at $2.92.The...
Robert Driscoll from Wedbush issued a price target of $2.00 for FHTX on 2026-10-02 10:49:02.The adjusted price target was set to $2.00.At the time of the announcement, FHTX was trading...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
